Literature DB >> 27830398

Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy.

Makiko Katagiri1, Jun Shoji2, Satoshi Kato3, Shigehiko Kitano4, Yasuko Uchigata5.   

Abstract

PURPOSE: We investigated the relationship between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and vascular endothelial growth factor (VEGF) and renal function, and correlations between vitreous sRAGE levels and proliferative diabetic retinopathy (PDR) activity.
METHODS: We examined 33 eyes from 33 patients with diabetes mellitus who underwent a vitrectomy (eight patients in the non-PDR [NPDR] group and 25 in the PDR group). Serum creatinine levels and estimated glomerular filtration rate (eGFR) were measured and classified according to the chronic kidney disease (CKD)-staging method. Enzyme-linked immunosorbent assay (ELISA) was performed to quantify vitreous sRAGE and VEGF levels.
RESULTS: Vitreous sRAGE levels were significantly higher in PDR group compared to NPDR group (p = 0.00003). Vitreous sRAGE levels were significantly higher in patients with CKD stage 5 (end-stage renal failure or hemodialysis) than in patients with CKD stage 1 or 2 (p < 0.01) and 3 or 4 (p < 0.05), and were significantly correlated with eGFR (r = - 0.490, p = 0.007) and creatinine levels (r = 0.484, p = 0.006). Within the PDR group, patients with low (<27 pg/mL) sRAGE levels required repeat vitreous surgeries for early postoperative vitreous hemorrhage significantly more frequently than those with high (≥27 pg/mL) sRAGE levels (p = 0.0067).
CONCLUSIONS: Vitreous sRAGE levels were significantly correlated with renal function, and low vitreous sRAGE levels in patients with PDR were associated with postoperative vitreous hemorrhage. Vitreous sRAGE may be a useful biomarker for renal dysfunction associated with diabetic retinopathy.

Entities:  

Keywords:  Postoperative vitreous hemorrhage; Proliferative diabetic retinopathy; Renal function; Soluble receptor for advanced glycation end products; Vascular endothelial growth factor; Vitreous fluid

Mesh:

Substances:

Year:  2016        PMID: 27830398     DOI: 10.1007/s10792-016-0389-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  21 in total

1.  Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes.

Authors:  H Takagi; G L King; L P Aiello
Journal:  Diabetes       Date:  1996-08       Impact factor: 9.461

2.  Soluble receptor for advanced glycation end products in patients with decreased renal function.

Authors:  Marta Kalousová; Magdaléna Hodková; Markéta Kazderová; Jana Fialová; Vladimír Tesar; Sylvie Dusilová-Sulková; Tomás Zima
Journal:  Am J Kidney Dis       Date:  2006-03       Impact factor: 8.860

3.  Upregulation of RAGE and its ligands in proliferative retinal disease.

Authors:  Sophia I Pachydaki; Samir R Tari; Song Eun Lee; Wanchao Ma; Joseph J Tseng; Alexander A Sosunov; Guellue Cataldergirmen; Nikolaos Scarmeas; Casper Caspersen; Stanley Chang; William M Schiff; Ann Marie Schmidt; Gaetano R Barile
Journal:  Exp Eye Res       Date:  2005-12-20       Impact factor: 3.467

4.  Disappearance of diabetic macular hard exudates after hemodialysis introduction.

Authors:  Toshihiko Matsuo
Journal:  Acta Med Okayama       Date:  2006-06       Impact factor: 0.892

5.  Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Authors:  Colomba Falcone; Enzo Emanuele; Angela D'Angelo; Maria P Buzzi; Chiara Belvito; Mariaclara Cuccia; Diego Geroldi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

Review 6.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.

Authors:  Sho-ichi Yamagishi; Tsutomu Imaizumi
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

Review 7.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.

Authors:  C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

8.  Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.

Authors:  Marta Kalousová; Marie Jáchymová; Oto Mestek; Magdaléna Hodková; Markéta Kazderová; Vladimír Tesar; Tomás Zima
Journal:  Nephrol Dial Transplant       Date:  2007-03-08       Impact factor: 5.992

9.  Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE).

Authors:  H Zong; M Ward; A Madden; P H Yong; G A Limb; T M Curtis; A W Stitt
Journal:  Diabetologia       Date:  2010-09-12       Impact factor: 10.122

10.  Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

Authors:  Jason B Lindsey; James A de Lemos; Francesco Cipollone; Colby R Ayers; Anand Rohatgi; David A Morrow; Amit Khera; Darren K McGuire
Journal:  Diabetes Care       Date:  2009-04-14       Impact factor: 19.112

View more
  2 in total

Review 1.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

2.  Relationship between renal function and prognosis of Chinese proliferative diabetic retinopathy patients undergoing the first vitrectomy: protocol for a prospective cohort study.

Authors:  Chunyan Lei; Keren Zhang; Tiancong Chang; Qibo Ran; Meixia Zhang
Journal:  BMJ Open       Date:  2021-12-06       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.